Why Tempus AI Skyrocketed This Week

TEM surged 39.5% this week after MRK and MRNA reported positive Phase 3 trial results for their jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The rally stems from Tempus AI's pending acquisition of PSNL, which developed the genomic tumor-profiling technology that underpins the vaccine's development. Despite the week's sharp gains, TEM remains down approximately 10% over the past year.

The Merck-Moderna collaboration marks a significant advance in personalized cancer treatment, combining mRNA technology with checkpoint inhibitor therapy. Tempus's planned purchase of Personalis positions the company to capture value from the genomic diagnostics essential to identifying patients who may benefit from the therapy. The market reaction reflects investor optimism that Tempus will play a central role in the commercial rollout if the vaccine reaches approval.